Earnings Routine +

NEUPATH HEALTH REPORTS FIRST QUARTER 2026 RESULTS

NeuPath Health Confirms Growth Trajectory Under New CEO Despite Margin Compression and Debt Settlement Risks

By The Northwire Desk — AI Analysis May 14, 2026 · 07:30 NPTH · 0.56 Neupath Health Inc.

Executive Summary

NeuPath Health Inc. reported First Quarter 2026 total revenue of $21.5 million, an 11% increase year-over-year compared to Q1 2025 ($19.3 million).
Adjusted EBITDA grew 15% year-over-year to $1.5 million for the period ended March 31, 2026.
The Company confirmed the appointment of Stephen Lemieux as Chief Executive Officer, effective April 1, 2026, following a pre-announced transition plan.
Clinic revenue reached $20.2 million, driven by increased patient visits and growth in Arthrosamid and fluoroscopy revenues.
Gross Margin % decreased slightly to 18.4% from 18.8% in the prior year period.
Physical Capacity Utilization increased to 52% from 47% in the prior year period.
Cash and cash equivalents stood at $3.5 million as of March 31, 2026.
Interest-bearing long-term debt is $6.0 million, resulting in a net debt position of $2.5 million.
Basic shares outstanding are 56,180,787 with fully diluted shares at 63,089,211.

Material Impact

The Q1 2026 results confirm the growth trajectory previously guided in January 2026 and reported in Q4 2025, indicating consistent execution under new leadership rather than a surprise catalyst.
Revenue growth of 11% is positive but shows deceleration compared to the 20% full-year growth achieved in FY 2025, suggesting potential saturation or market headwinds that limit upside materiality.
The debt settlement announced April 1, 2026 ($420k owed to former CEO/CFO) remains pending shareholder approval on June 10, 2026; this creates a near-term overhang rather than immediate positive impact.
Gross margin compression (18.4% vs 18.8%) is a negative signal regarding cost control or pricing power that offsets the EBITDA growth headline.
The stock price has already doubled from $0.21 to ~$0.56 over the past year, largely pricing in this level of performance; therefore, the news lacks the "unexpected" element required for a Material - Positive rating.

NPTH · Price

Company Overview

NeuPath Health Inc. operates medical imaging and rehabilitation clinics across Ontario.
Flagship operations include physical therapy services, fluoroscopy, and Arthrosamid treatments (a viscosupplementation product for knee osteoarthritis).
The business model relies on high utilization of physician shifts and clinic capacity to drive revenue per location.
Strategic focus is on expanding the footprint (e.g., Guelph opening) while optimizing existing facility margins.

More from Neupath Health Inc.